Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05043792 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects

A Phase 1 study of Healthy, sponsored by TransThera Sciences (Nanjing).

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT05043792 is a Phase 1 study of Healthy that has completed, run by TransThera Sciences (Nanjing). The registered enrollment target is 20 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05043792, a Phase 1 study of Healthy, has completed, sponsored by TransThera Sciences (Nanjing).

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is a double-blind, randomized, placebo-controlled, multiple ascending dose escalation study of TT-00920 in healthy subjects.

Conditions Studied

Interventions

  • DRUG TT-00920
  • DRUG TT-00920 Placebo

Study Locations (1)

Maryland

  • Pharmaron CPC, Inc. - Baltimore

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-08-19
Est. Completion 2021-11-30
Phase Phase 1

Sponsor

TransThera Sciences (Nanjing)

7 total trials

What the Registry Record Tells You About NCT05043792

The ClinicalTrials.gov registry entry for NCT05043792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is TransThera Sciences (Nanjing), which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which TT-00920 is the first listed.

NCT05043792 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT05043792 about?

NCT05043792 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects". This is a double-blind, randomized, placebo-controlled, multiple ascending dose escalation study of TT-00920 in healthy subjects.

What is the current status of trial NCT05043792?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-08-19. Estimated completion is 2021-11-30.

What conditions does trial NCT05043792 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05043792?

The interventions under investigation include: TT-00920 (DRUG), TT-00920 Placebo (DRUG).

Who is sponsoring clinical trial NCT05043792?

This trial is sponsored by TransThera Sciences (Nanjing), which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05043792 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.